Article Text

PDF

Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up
  1. Z Mahmood1,
  2. B P McMahon2,
  3. Q Arfin1,
  4. P J Byrne3,
  5. J V Reynolds3,
  6. E M Murphy4,
  7. D G Weir1
  1. 1Department of Clinical Medicine, Trinity College, St James’s Hospital, Dublin, Ireland
  2. 2Department of Medical Physics and Clinical Engineering, AMNCH, Dublin
  3. 3Department of Surgery, Trinity College, St James’s Hospital, Dublin, Ireland
  4. 4Department of Medical Physics and Bioengineering, Trinity College, St James’s Hospital, Dublin, Ireland
  1. Correspondence to:
    Professor D G Weir, Department of Clinical Medicine, Trinity Centre for Health Sciences, St James’s Hospital, Dublin 8, Ireland;
    dweir{at}tcd.ie

Abstract

Background: Gastro-oesophageal reflux disease (GORD) is, in the main, treated with either proton pump inhibitor (PPI) drugs or a Nissen fundoplication operation. Recently, BARD developed Endocinch, a device used to place sutures just below the oesophagogastric junction (OGJ) to treat GORD.

Aim: To evaluate the long term benefit of the Endocinch technique in patients seen up to 12 months post procedure.

Patients: Twenty six patients with symptoms of GORD were recruited and had the procedure performed. Four patients were lost to follow up.

Methods: Twenty two patients completed their one year follow up. Pre procedure and post procedure (up to 12 months) assessments included symptom scoring (DeMeester), upper intestinal endoscopy, oesophageal manometry and 24 hour oesophageal pH, and completion of quality of life (QOL) questionnaires.

Results: Mean age was 39 years (range 22–62). Heartburn symptom score was reduced from a mean value of 19.22 at baseline to 7.5 at 12 months (n=22) (p<0.0001). Regurgitation score reduced from a mean of 2.27 at baseline to 0.86 at 12 months (n=22) (p<0.001). Mean (SEM) pH DeMeester acid score was reduced from 44.1 (4.3) to 33.32 (4.73) (p=0.028) at three month post procedure. Percentage upright acid exposure and number of reflux episodes were also reduced significantly. Use of PPIs was reduced by 64% at 12 months post procedure. All QOL assessments showed significant improvement (p=0.01). All transient post procedure complaints resolved within 72 hours.

Conclusion: The Endocinch procedure is an effective and safe outpatient procedure that offers GORD patients significant improvement in symptomatology, QOL, and reduced requirements for PPIs over at least a one year period.

  • gastro-oesophageal reflux disease
  • manometry
  • Endocinch
  • endoscopic plication
  • GORD, gastro-oesophageal reflux disease
  • PPI, proton pump inhibitor
  • OGJ, oesophagogastric junction
  • QOL, quality of life
  • LNF, laparoscopic Nissen fundoplication
  • BMI, body mass index
  • LOS, lower oesophageal sphincter
  • TLOSR, transient lower oesophageal sphincter relaxation
View Full Text

Statistics from Altmetric.com

Footnotes

  • Conflict of interest: The authors have been the principal teachers of the Endocinch technique for BARD in Europe over the past two years.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Ian Forgacs